Background and aims: Recently, thioredoxin-interacting protein (Txnip) expression has been implicated in a number of cellular events associated with diabetes, with increased Txnip levels associated with reduced glucose uptake into peripheral tissues, increased reactive oxygen species (ROS) in endothelial cells, beta cell glucotoxicity and apoptosis. The potential relevance of Txnip with regards to glucose-regulated insulin secretion (GSIS), a fundamentally important characteristic of beta cells and insulin-producing cells being considered as a possible cell therapy for diabetes, has not yet been investigated. Methods: Here, studying glucose-responsive MIN6 B1(GSIS) and cells which had significantly reduced response to glucose after time in culture i.e. MIN6 B1(Non-GSIS), using ELISAs; qRT-PCR; immunoprecipitation and Western blotting; transient and stable (siRNA/shRNA and cDNA) approaches to achieve Txnip knock-down or over-expression, respectively,we established a direct association between Txnip expression and GSIS. Results: Specifically, increasing Txnip levels correlate with increased intracellular ROS levels and with significant GSIS loss.Conversely, both transient and stable knock-down of Txnip expression was associated with GSIS recovery. Conclusion: This, we believe, is another reason in favour of targeting Txnip as a novel approach for diabetes-related therapy.

Keywords:
Txnip, Glucose-stimulated insulin secretion, Immunoprecipitation, ROS, siRNA, shRNA, cDNA
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.